Hagop Youssoufian, MD
Verastem, Inc.
20
0
10
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+11 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (20)
Showing 10 of 20 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Areej El-Jawahri, MD
Massachusetts General Hospital
Shared therapeutic areas:
Francesco Perrone, M.D., Ph.D.
National Cancer Institute, Naples
Shared therapeutic areas:
Britt Burton-Freeman, ph.D
Illinois Institute of Technology
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Shared therapeutic areas:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Paolo Bonato, PhD
Spaulding Rehabilitation Hospital
Shared therapeutic areas:
Herbert B Slade, MD
Healthpoint
Shared therapeutic areas:
loic MONDOLONI
Assistance Publique Hopitaux De Marseille
Shared therapeutic areas:
Hamid Gourabi, PhD
head of Royan Institute
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (20)
Showing 20 of 20 trials
Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study
A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam
Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
All 20 trials loaded